HAE Haemonetics Corporation

Evaluate Haemonetics' (HAE) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Haemonetics Corp HAE reported upbeat earnings for the first quarter on Thursday. The company posted quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.02 per share. The company reported quarterly sales of $321.394 million which beat the analyst consensus ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Haemonetics (HAE) delivered earnings and revenue surprises of +8.91% and +5.97%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Haemonetics ( NYSE:HAE ) , a medical technology company specializing in blood and plasma collection and hospital technologies, reported its financial results for the first quarter of fiscal 2026 on August 7, 2025. The main headlines from the release included GAAP revenue of $321.4 million for Q1 ...

Haemonetics's HAE short percent of float has fallen 4.44% since its last report. The company recently reported that it has 3.50 million shares sold short, which is 11.84% of all regular shares that are available for trading.